AstraZeneca's Crestor to challenge Pfizer's Lipitor In Korea

AstraZeneca's Crestor (rosuvastatin), which is expected to be launched during the first half of this year, will race to catch up Korea's market share, posing a threat to Pifzer's Lipitor (atorvastatin) in the antihyperlipemic market.

Market analysts project that competition between foreign-invested pharmaceutical firms over the domestic antihyperlipemic market is expected to become fierce, a...